Drug Profile
Research programme: immunoconjugates - Biocon/IATRICa
Alternative Names: Immunoconjugated MAbs - Biocon/IatriCaLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Biocon; IATRICa
- Class Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in India (Parenteral)
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for research development in Infections in India (Parenteral)